



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gevas et al.  
Serial No. : 10/829,137  
Filed : April 21, 2004

Art Unit : 1631  
Examiner : Michael L. Borin  
Cust. No. : 20985  
Conf. No. : 6164

Title : PREVENTION AND TREATMENT OF HYPERGASTRINEMIA

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (8 pages), cited non U.S. patent documents listed on the form PTO-1449, documents listed in table of Supplementary Information Disclosure Statement (27 documents, including 2 Australian Examination Reports and 7 U.S. Office Actions), and a return postcard for filing in connection with the above-captioned application. Because this Supplemental Information Disclosure Statement is filed with a Request for Continued Examination and prior to receipt of a first Office Action on the merits for the above-captioned application, a fee for filing this statement should not be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No, 06-1050, as stated below:


☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
Stephanie Seidman  
Reg. No. 33,779

Attorney's Docket No.: 17118-059US2 / 2838BUS  
**Address all correspondence to:**  
Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com  
SLS/jtt

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 965983413 US  
Date of Deposit July 18, 2007  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

  
Stephanie Seidman



UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gevas et al.  
Serial No. : 10/829,137  
Filed : April 21, 2004

Art Unit : 1631  
Examiner : Michael L. Borin  
Cust. No. : 20985  
Conf. No. : 6164

Title : PREVENTION AND TREATMENT OF HYPERGASTRINEMIA

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

This Supplemental Information Disclosure Statement is filed with a Request for Continued Examination of the above-captioned application and prior to receipt of an Office Action. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (8 pages) and copies of the cited non U.S. Patent documents are provided herewith in connection with the above-captioned application.

The documents cited on the Forms PTO-1449 are in the English language, with the exception of items noted below. Item CQ (Kameyama, *et al.*) is in the Japanese language and is provided with an English language summary on the last page of the article. Item FA (Trakal *et al.*) is in the Spanish language and is provided with an English language abstract on the first page of the article.

In accordance with the requirements of 37 C.F.R. §1.98, the following documents are provided for consideration by the Examiner:

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 965983413 US

Date of Deposit July 18, 2007

I hereby certify that this paper is being deposited with the United States Postal "Express Mail/Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

1) Office Action, issued August 9, 1996, in connection with U.S. Patent Application Serial No. 08/462,158, now U.S. Patent 5,785,970 (Attorney Docket No. 17118-054US3/2833CUS).

2) Office Action, issued August 12, 1996, in connection with U.S. Patent Application Serial No. 08/465,546, now U.S. Patent 5,866,128 (Attorney Docket No. 17118-054005/2833E).

3) Office Action, issued June 24, 1998, in connection with U.S. Patent Application Serial No. 08/798,423 (Attorney Docket No. 17118-056001/2835).

4-6) Office Actions, issued March 23, 2005, November 1, 2005 and December 27, 2006, in connection with U.S. Patent Application Serial No. 10/762,226 (Attorney Docket No. 17118-056002/2835B).

7) Office Action, issued April 3, 2003, in connection with U.S. Patent Application Serial No. 09/700,329 (Attorney Docket No. 17118-059US1/2838US), which is a National Stage Entry of International Patent Application No. PCT/US99/10751. In the Office Action, the Examiner cites 4 documents: i) US 5607676; ii) Sundler *et al.*, "The neuroendocrine system of the gut--an update" *Acta Oncol.* 30(4):419-427 (1991); iii) Watson *et al.*, "Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer" *Cancer Res.* 56:880-885 (1996); iv) Watson *et al.*, "Anti-gastrin antibodies raised by gastrimmune inhibit growth of colorectal tumor AP5" *Int. J. Cancer*, 61(2):233-240 (1995).

8-9) Office Actions, issued January 15, 2003 and July 13, 2001, in connection with corresponding Australian Patent Application No. 40803/99 (Attorney Docket No. 17118-059AU1/2838AU), which is a National Stage Entry of International Patent Application No. PCT/US99/10751. In Office Actions 8 and 9, the Examiner cites the following Patents: i) US 5023077; ii) US 5468494; iii) US 5607676; iv) US 5609870; and v) US 5622702. In the Office Action dated July 13, 2001, the Examiner also cites Watson *et al.*, "Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer" *Cancer Res.* 56:880-885 (1996); and Watson *et al.*, "Anti-gastrin antibodies raised by gastrimmune inhibit growth of colorectal tumor AP5" *Int. J. Cancer*, 61(2):233-240 (1995).

In Office Actions 1 and 2, the Examiner cites five documents: i) US 4526716; ii) Bowie *et al.*, "Deciphering the message in protein sequences: Tolerance to amino acid substitutions" *Science* 247:1306-1310 (1990); iii) Houghton *et al.*, "Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: Implications in the mechanism of antigenic drift and antigenic shift" *Vaccine* 86:21-25 (1986); iv) Iwanaga *et al.*, "Immunocytochemical localization of the different gastrin forms in the pyloric antrum" *Biomed. Res.* 1:316-320 (1980); and v) Siemann, "Satisfactory and unsatisfactory tumor models: Factors influencing the selection of a tumor model for experimental evaluation", *Rodent Tumor Models in Experimental Cancer Therapy* (Ed. Kallman) Pergamon Press, NY: 12-15 (1987)

The instant application is a continuation of U.S. Application Serial No. 09/700,329, which is a National Stage Entry of PCT/US99/10751.

In addition, copies of other documents are provided (documents 10-27). The table below lists Documents 1-27 and includes a column that provides a space next to each document to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	1	Copy of Office Action, issued August 9, 1996, in connection with U.S. Patent Application Serial No. 08/462,158, now U.S. Patent 5,785,970
	2	Copy of Office Action, issued August 12, 1996, in connection with U.S. Patent Application Serial No. 08/465,546, now U.S. Patent 5,866,128
	3	Copy of Office Action, issued June 24, 1998, in connection with U.S. Patent Application Serial No. 08/798,423
	4	Copy of Office Action, issued March 23, 2005, in connection with U.S. Patent Application Serial No. 10/762,226
	5	Copy of Office Action, issued November 1, 2005, in connection with U.S. Patent Application Serial No. 10/762,226
	6	Copy of Office Action, issued December 27, 2006, in connection with U.S. Patent Application Serial No. 10/762,226
	7	Copy of Office Action, issued April 3, 2003, in connection with U.S. Patent Application Serial No. 09/700,329
	8	Copy of Office Action, issued January 15, 2003, in connection with corresponding Australian Patent Application No. 40803/99
	9	Copy of Office Action, issued July 13, 2001, in connection with corresponding Australian Patent Application No. 40803/99
	10	Caplin <i>et al.</i> , "Expression and processing of gastrin in pancreatic adenocarcinoma" <i>Brit. J. Surgery</i> 87:1035-1040 (2000)

Examiner Initial	Document No.	Document
	11	Dickson <i>et al.</i> , "Helicobacter pylori Can Induce Heparin-Binding Epidermal Growth Factor Expression via Gastrin and its Receptor" <i>Cancer Research</i> 66:7524-7531 (2006)
	12	Dufresne <i>et al.</i> , "Cholecystokinin and Gastrin Receptors", <i>Physiol Rev.</i> 86:805-847 (2006)
	13	Gallo-Torres, H.E., <i>et al.</i> , Excerpts from the Nexium™ Investigational New Drug Application, 8 pgs., (2001).
	14	Gilliam <i>et al.</i> , "A Phase II study of G17DT in gastric carcinoma" <i>EJSO</i> 30:536-543 (2004)
	15	Gilliam <i>et al.</i> , "Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy" <i>J. Clin. Oncol. ASCO Annual Meeting Proceedings</i> 22(14S):2511 (2004)
	16	Harris <i>et al.</i> , "The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas", <i>Cancer Res.</i> 64:5624-5631 (2004)
	17	Henwood <i>et al.</i> , "Expression of gastrin in developing gastric adenocarcinoma" <i>Br. J. Surgery</i> 88:564-568 (2001)
	18	Kuipers <i>et al.</i> , "The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease" <i>Gastroenterology</i> 118:795-798 (2000)
	19	Lamberts <i>et al.</i> , "Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa", <i>Digestion</i> 64:205-213 (2001)
	20	Pannequin <i>et al.</i> , "Divergent roles for ferric ions in the biological activity of amidated and non-amidated gastrins" <i>J. Endocrinol.</i> 181(2):315-325 (2004)
	21	"Prilosec OTC Review: Two Advisory Cmte. Members Weigh in Without Voting", <i>The Pink Sheet</i> pp 22-23, (2002)
	22	Schmitz <i>et al.</i> , "CCK-B/gastrin receptors in human colorectal cancer" <i>European J. Clinical Investigation</i> 31:812-820 (2001)
	23	Senior, "Immunization blocks gastrin's ability to promote tumour cell division" <i>Drug Disc. Today</i> 6(2):62-63 (2001)
	24	Takhar <i>et al.</i> , "The role of gastrin in colorectal carcinogenesis" <i>J. R. Coll. Surg. Edinb. Irel.</i> 2(5):251-257 (2004)
	25	Von Hoff <i>et al.</i> , "New drugs for patients with pancreatic cancer" <i>Curr. Opin. Oncology</i> 14:621-627 (2002)
	26	Watson <i>et al.</i> , "Enhanced inhibition of Pancreatic Cancer by Combination of the G17DT Immunogen and Gemcitabine" <i>Amer. Soc. Clin. Oncol. Abstract</i> 37 (2002)
	27	Watson <i>et al.</i> , "Synergistic inhibitory effects of G17DT on gastrointestinal tumor growth in combination with cytotoxic agents" <i>Proc. Am. Soc. Clin. Oncol.</i> 22:2003 (abstr 3497) (2003)

Applicant also makes known to the Examiner the following U.S. applications, which are commonly owned and/or have one or more inventors in common:

Applicant : Gevas *et al.*  
Serial No. : 10/829,137  
Filed : April 21, 2004


Attorney's Docket No.: 17118-059US2/ 2838BUS  
Supplemental Information Disclosure Statement

<u>Serial No.</u>	<u>Filing Date</u>	<u>Docket No.</u>
09/700,402	12/04/01	17118-061US1/ 2840US
11/360,378	02/22/06	17118-062002/ 2841B
11/499,261	08/03/06	17118-064003/ 2843C
11/808,889	05/07/07	17118-064004/ 2843D
11/659,937	02/09/07	17118-066US1/ 2845US
11/663,126	03/16/07	17118-067US1/ 2846US
11/036,690	01/14/05	17118-073003/ 2849C
11/489,775	07/20/06	17118-073004/ 2849D
11/492,695	07/25/06	17118-073005/ 2849E

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the documents or information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

Respectfully submitted,

  
Stephanie Seidman  
Reg. No. 33,779

Attorney's Docket No.: 17118-059US2 / 2838BUS

**Address all correspondence to:**

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com

SLS/jtt


Substitute Form PTO-449  
(Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.  
17118-  
059US2/2838BUS

Application No.  
10/829,137

**List of Patents and Publications for Applicant's  
Information Disclosure Statement**

(37 CFR §1.98(b))

Applicant  
Gevas et al.

Filing Date  
April 21, 2004

Group Art Unit  
1631

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2001/0020005	09/06/01	Chowers et al.	514	008	12/15/00
	AB	2005/0169979	8/4/05	Michaeli et al.	424	184.100	01/14/05
	AC	2007/0065454	3/22/2007	Michaeli et al.	424	184.1	07/20/06
	AD	2007/0082043	4/12/2007	Michaeli et al.	424	184.1	07/25/06
	AE	4,302,386	11/24/1981	Stevens	260	112.5	04/15/85
	AF	4,767,842	8/30/1998	Stevens	530	324	07/15/87
	AG	4,794,103	12/27/1988	Bertolini	514	12	01/02/87
	AH	4,978,683	12/18/90	Rovati et al.	514	617	12/05/85
	AI	5,006,334	04/91	Stevens	424	195.11	07/15/87
	AJ	5,698,201	12/16/97	Stevens	424	195.11	06/06/95
	AK	5,750,119	05/12/98	Srivastava	424	277.1	09/30/94
	AL	5,759,551	06/02/98	Ladd et al.	424	198.100	12/26/95
	AM	5,786,213	7/28/98	Singh et al.	435	320.100	04/18/96
	AN	5,843,446	12/1/1998	Ladd et al.	424	184.1	06/07/95
	AO	6,187,536	02/13/01	Weinberg et al.	435	6	02/18/98
	AP	6,696,262	02/24/04	Harkonen	435	7.32	03/14/01

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AQ	00/67035	11/09/00	PCT				
	AR	01/34192	05/17/01	PCT				
	AS	2006/008649	01/26/06	PCT				
	AT	2006/016275	02/16/06	PCT				
	AU	94/00590	01/06/94	PCT				
	AV	95/21380	08/10/95	PCT				
	AW	96/15456	05/23/96	PCT				
	AX	99/19353	04/22/99	PCT				

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118- 059US2/2838BUS	Application No. 10/829,137
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>		Applicant Gevas et al.	
		Filing Date April 21, 2004	Group Art Unit 1631
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AY	ATCC Accession No. 49503, <a href="http://www.atcc.org">www.atcc.org</a> , (accessed on 07.17.2007).
	AZ	Baldwin, G., et al., "Binding of the progastrin fragments to the 78KDA gastrin-binding protein," FEBS Letters, 359:97-100, (1995).
	BA	Baldwin, G.S. and A. Shulkes, "Gastrin, gastrin receptors and colorectal carcinoma," Gut, 42:581-584, (1998).
	BB	Baldwin, G.S., and Q. Zhang, "Measurement of gastrin and transforming growth factor a messenger RNA levels in colonic carcinoma cell lines by quantitative polymerase chain reaction," Cancer Research, 52:2261-2267, (1992).
	BC	Behr, T.M., et al., "Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential," Clinical Cancer Research, 5(10 Suppl):3124s-3138s, (1999).
	BD	Bentley, P.H., et al., "Human gastrin: isolation, structure and synthesis: structures of human gastrins I and II," Nature, 209(5023):583-585, (1966).
	BE	Biagini, P., et al., "The human gastrin/cholecystokinin receptors: Type B and type C expression in colonic tumours and cell lines," Life Sciences, 61(10):1009-1018, (1997).
	BF	Bock, M.G., et al., "Benzodiazepine, gastrin and brain cholecystokinin receptor ligands: L-365,260," Journal of Medicinal Chemistry, 32:13-17, (1989).
	BG	Boland, C.R., "Gastrin and colorectal neoplasia--chicken or egg, or both," Journal of Clinical Gastroenterology, 13(5):497-499, (1991).
	BH	Bold, R., et al., "Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B," Biochemical and Biophysical Research Communications, 202(3):1222-1226, (1994).
	BI	Brett, B.T., et al., "Lymphocyte expression of the CCK-B/gastrin receptor (CCK-BR) in gastric lymphomas, Helicobacter pylori gastritis and normal gastric biopsies," Gastroenterology, 114: (Supplement 1): A570 (Abstract #G2333) (April 15, 1998)
	BJ	Brett, B.T., et al., "Lymphocyte sub-populations in helicobacter pylori (HP) gastritis, low-grade gastric malt lymphoma and high grade gastric lymphoma," Gastroenterology, 114(Supplement 1):A942, (Abstract # G3860) (April 15, 1998).
	BK	Brett, B.T., et al., "The effect of antibodies raised against gastrin on the proliferation of human pancreatic carcinoma cell lines," Gut, 42(Suppl.):A26, (Abstract # W190) (1998).
	BL	Bystryn, J., "Tumor vaccines," Cancer and Metastasis Reviews, 9:81-91, (1990).
	BM	Caplin, M.E., et al., "Expression and processing of gastrin in patients with hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma," Gastroenterology, 114(Supplement 1):A1219, (Abstract # L0083) (April 15, 1998).
	BN	Caplin, M.E., et al., "Expression and processing of gastrin in patients with pancreatic carcinoma," Gastroenterology, 114(Supplement 1):A445, (Abstract # G1809) (April 15, 1998).
	BO	Chaudhry, A., et al., "Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer," Clinical Cancer Research, 5:3385-3393, (1999).

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118- 059US2/2838BUS	Application No. 10/829,137
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))				Applicant Gevas et al.	
				Filing Date April 21, 2004	Group Art Unit 1631
<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>					
Examiner Initial	Desig. ID	Document			
	BP	Choudhry, U., et al., "Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics," American Journal of Clinical Pathology, 110(5):615-621, (1998).			
	BQ	de Weerth, A., et al., "Human pancreatic cancer cell lines express the CCKB receptor," Hepatogastroenterology, 46:472-478, (1999).			
	BR	de Weerth, A., et al., "Human pancreatic cancer cell lines express the CCKB/gastrin receptor," Gastroenterology, A289, (1994).			
	BS	Del Valle, J., et al., "Progastrin and its glycine-extended posttranslational processing intermediates in human gastrointestinal tissues," Gastroenterology, 92:1908-1912, (1987).			
	BT	Dethloff, L.A., et al., "Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988," Food and Chemical Toxicology, 37:105-110, (1999).			
	BU	Dickinson, C.J., "Relationship of gastrin processing to colon cancer," Gastroenterology, 109:1384-1388, (1995).			
	BV	Dockray, G., et al., "Gastric endocrine cells: gene expression, processing, and targeting of active products," Physiological Review, 76(3):767-798, (1996).			
	BW	Edgington, S., "Biotech vaccines' problematic promise," Bio/Technology, 10:763-766, (1992).			
	BX	Edkins, J.S., "On the chemical mechanism of gastric secretion," Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character, 76: 376, (1905).			
	BY	Edkins, J.S., "The chemical mechanism of gastric secretion," Journal of Physiology, 34(1-2):133-144 (March 13, 1906).			
	BZ	Fennerty, B., "Update on barrett's esophagus," Digestive Diseases Week, May 22, 2001, meeting report published by Medscape, www.medscape.com, 6 pgs.			
	CA	Feurle, G., et al. "The role of CCK and its analogues in the organogenesis of the fetal rat pancreas," Pancreas, 10:281-286, (1995).			
	CB	Finley, G., et al., "Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma," Cancer Research, 53:2919-2926, (1993).			
	CC	Fourmy, D., et al., "Relationship of CCK/gastrin receptor binding to amylase release in dog," Regulatory Peptides, 10:57-68, (1984).			
	CD	Frucht, H. et al., "Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells," Cancer Research, 52(5):1114-1122, (1992).			
	CE	Grider, J.R. and G.M. Makhlof, "Distinct receptors for cholecystokinin and gastrin" American Journal of Physiology, 259:G184-G190, (1990).			
	CF	Gupta, R. and G. Siber, "Adjuvants for human vaccines - current status, problems and future prospects," Vaccine, 13(14):1263-1276, (1995).			
	CG	Harrison, J.D., et al., "The effect of the gastrin receptor antagonist proglumide on survival in gastric carcinoma," Cancer, 66(7):1449-1452, (1990).			
	CH	Hoosein, N.M., et al., "Anti-proliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines," Cancer Research, 48:7179-7183, (1988).			
	CI	Hughes, J., et al., "Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity," Proceedings of the National Academy of Sciences of the United States of America, 87:6728-6732, (1990).			
Examiner Signature			Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118- 059US2/2838BUS	Application No. 10/829,137
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))			Applicant Gevas et al.	
			Filing Date April 21, 2004	Group Art Unit 1631
<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>				
Examiner Initial	Desig. ID	Document		
	CJ	Ichikawa, T., et al., "Distinct effects of tetragastrin, histamine, and CCh on rat gastric mucin synthesis and contribution of NO," American Journal of Physiology, 274(1):G138-G146, (1998).		
	CK	Iwase, K., et al., "Regulation of growth of human gastric cancer by gastrin and glycine-extended pro-gastrin," Gastroenterology, 113:782-790, (1997).		
	CL	Jaffe, B.M., et al., "Inhibition of gastrin activity with antibodies to C-terminal tetrapeptide of gastrin," Surgery, 65(4):633-639, (1969).		
	CM	Johnson, L., "New aspects of the trophic action..." Gastroenterology 72:788-792 (1977)		
	CN	Johnson, L.R., et al., "Ornithine decarboxylase in large bowel mucosa: regulation by gastrin, secretin and EGF," Journal of Physiology and Pharmacology, 43(1):33-41, (1992).		
	CO	Joshi, S. and J. Gardner, "Gastrin and colon cancer: a unifying hypothesis," Digestive Diseases, 14:334-344, (1996).		
	CP	Justin, T. and R. Steele et al., "Gastric acid suppression using anti-gastrin 17 antibodies produced by a gastrin immunogen, Gastrimmune, in an in vivo pig model," Gastroenterology, 108(4):A125, (1995).		
	CQ	Kameyama, M., et al., "Adjuvant Chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer," Gan. To. Kagaku Ryoho [Japanese Journal of Cancer and Chemotherapy], 21(13):2169-2171, (1994) [in Japanese, English summary on last page of article]		
	CR	Katoh, H., et al., "Malignant zollinger-ellison syndrome. Stabilizing of liver metastasis after gastrectomy with resection of primary tumor," American Surgeon, 56(6):360-363, (1990).		
	CS	Kaufmann, R., et al., "Cholecystokinin B-type receptor signaling is involved in human pancreatic cancer cell growth," Neuropeptides, 31(6):573-583, (1997).		
	CT	Kelly, A., et al., "Pathophysiology of GI tract and liver," Journal of Gastroenterology and Hepatology, 13:208-214, (1998).		
	CU	Kobori, O., et al., "Growth response of rat stomach cancer cells to gastro-entero-pancreatic hormones," International Journal of Cancer, 30:65-67, (1982).		
	CV	Kochman, M.L., et al., "Post-translational processing of gastrin in neoplastic human colonic tissues," Biochemical and Biophysical Research Communications, 189(2):1165-1169, (1992).		
	CW	Koelz, H.R., "Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials," Scandinavian Journal of Gastroenterology, 156:25-36, (1989).		
	CX	Koh, T., et al., "Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice," Gastroenterology, 113(3):1015-1025, (1997).		
	CY	Koh, T., et al., "Glycine-extended gastrin promotes the growth of a human hepatoma cell line," Gastroenterology, 110(4):1089, (1996).		
	CZ	Kopin, A.S., et al. "Expression, cloning and characterization of the canine perietal cell gastrin receptor," Proceedings of the National Academy of Sciences of the United States of America, 89:3605-3609, (1992).		
	DA	Kovacs, T., et al. "Inhibition of sham feeding-stimulated acid secretion in dogs by immunoneutralization of gastrin," American Journal of Physiology, 273 (2 Pt 1):G399-403, (1997).		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118- 059US2/2838BUS	Application No. 10/829,137
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))			Applicant Gevas et al.	
			Filing Date April 21, 2004	Group Art Unit 1631
<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>				
Examiner Initial	Desig. ID	Document		
	DB	Kovacs, T., et al., "Gastrin is a major mediator of the gastric phase of acid secretion in dogs:Proof by monoclonal antibody neutralization," Gastroenterology, 97:1406-1413, (1989).		
	DC	Le Meuth, V., et al., "Differential expression of A- and B-subtypes of cholecystokinin/gastrin-receptors in the developing calf pancreas," Endocrinology, 133:1182-1191, (1993).		
	DD	Lee, Y., et al., "The Human Brain Cholecystokinin-B/Gastrin Receptor" Journal of Biological Chemistry, 268(11):8164-8169, (1993).		
	DE	MacKenzie, J.F., et al., "Development of a radioligand binding assay to characterize gastrin receptors in the human gastrointestinal tract," Gut, 38:A37, (1996).		
	DF	Makishima, R., et al., "Active immunization against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats," Gastroenterology, 106:A824, (1994).		
	DG	Makishima, R., et al., "Inhibition of Gastrin-17 Stimulated acid secretion through active immunization in rats," FASEB Journal, 8:A92, Abs. 535, (1994).		
	DH	Mandair, K.K., et al., "Cholecystokinin receptors in human pancreatic cancer cell lines," European Journal of Cancer, 34:1455-1459, (1998).		
	DI	Marino, L., et al. "Expression and post-translational processing of gastrin in heterologous endocrine cells," Journal of Biological Chemistry, 266(10):6133-6136, (1991).		
	DJ	Matsumoto, M., et al. "Gastrin receptor characterization: affinity cross-linking of the gastrin-receptor on canine gastric parietal cells," American Journal of Physiology, 252:G143, (1987).		
	DK	McRae, L.J., et al., "Role of gastrin and gastrin receptors in the growth of human colon carcinoma cells," Journal of Cell Biology, 103(22a):74, (1986).		
	DL	McWilliams, D.F., et al., "Coexpression of gastrin and gastrin receptors (CCK-B and CCK-B) in gastrointestinal tumour cell lines," Gut, 42:795-798, (1998).		
	DM	Miyake, A., "A truncated form of human CCK-B/gastrin receptor generated by alternative usage of a novel exon," Biochemical and Biophysical Research Communications, 208(1):230-237, (1995).		
	DN	Mu, F., et al., "Monoclonal antibody to the gastrin receptor on parietal cells recognizes a 78-kDa protein," Proceedings of the National Academy of Sciences of the United States of America, 84:2698-2702, (1987).		
	DO	Nakata, H., et al., "Cloning and characterization of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis," Biochemical and Biophysical Research Communications, 187:1151-1157, (1992).		
	DP	Negre, F., et al., "Autocrine stimulation of AR4-2J rat pancreatic tumour cell growth by glycine-extended gastrin," International Journal of Cancer, 66(5):653-658, (1996).		
	DQ	Nemeth, J., et al., "Identification of progastrin derived peptides in colorectal carcinoma extracts," Gut, 34:90-95, (1993).		
	DR	Nieschlag, E.,(Ed.), "Immunization with hormones in reproduction research," Proceedings of the International Symposium on Immunization with Hormones in Reproduction Research, Amsterdam: North Holland Publishing, pp. 107-117, (1975).		
	DS	Ochiai, A., et al., "Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1," Japan Journal of Cancer Research, 76:1064-1071, (1985).		
	DT	Ohkura, H., et al., "Gastrin-enhanced tumor growth of a xenotransplantable human gastric carcinoma in nude mice" Japanese Journal of Clinical Oncology, 10(2):255-263, (1980).		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118- 059US2/2838BUS	Application No. 10/829,137
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))			Applicant Gevas et al.	
			Filing Date April 21, 2004	Group Art Unit 1631
<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>				
Examiner Initial	Desig. ID	Document		
	DU	Okada et al., "Evaluation of cholecystokinin, gastrin, CCK-A receptor and CCK-B/gastrin receptor gene expressions in gastrin cancer" Cancer Letters 106(2):257-262 (1996)		
	DV	Palnaes, C., et al., "Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man," Digestion, 57:22-29, (1996).		
	DW	Parsonnet, J., et al., "Helicobacter pylori infection and the risk of gastric carcinoma," New England Journal of Medicine, 325:1127-1131, (1991).		
	DX	Redmond, E., et al. in "Gastroesophageal Reflux Disease," Ronald Hinder ed., R.G. Landes Co., pp1-6 (1993).		
	DY	Rehfeld, J.F., "Three Components of Gastrin in Human Serum," Biochemical and Biophysical Acta, 285:364-372, (1972).		
	DZ	Rehfeld, J.F., et al., "Cell-specific processing of pro-cholecystokinin and pro-gastrin," Biochimie, 70:25-31, (1988).		
	EA	Rehfeld, J.F., et al., "Gastrin in human bronchogenic carcinomas: constant expression but variable processing of progastrin," Cancer Research, 49:2840-2843, (1989).		
	EB	Roberston, J., et al., "Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer," International Journal of Cancer, 63:69-74, (1995).		
	EC	Romani, R., et al. "Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro," Australia and New Zealand Journal of Surgery, 66:235-237, (1996).		
	ED	Romani, R., et al., "Potent new family of gastrin receptor antagonists (GRAs) produces in vitro and in vivo inhibition of human colorectal cancer cell lines," Proceedings of the AACR, 35:397, (Abstract) (1994).		
	EE	Scemama, J.L., et al., "Characterization of gastrin-receptors on a rat pancreatic acinar cell line (AR4-2J). A possible model for studying gastrin mediated cell growth and proliferation," Gut 28:233-236, (1987).		
	EF	Seitz, J., et al., "Elevated serum gastrin levels in patients with colorectal neoplasia," Journal of Clinical Gastroenterology, 13(5):541-545, (1991).		
	EG	Seva, C., et al., "Characterization of the glycine-extended gastrin (G-gly) receptor on AR 42Z cells," Gastroenterology, A1005, (1995).		
	EH	Seva, C., et al., "Lorglumide and loxglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J)," Cancer Research, 50(18):5829-5833, (1990).		
	EI	Singh, P., et al., "High levels of progastrin significantly increase premalignant changes in colonic mucosa of mice in response to the chemical carcinogen, AOM," Gastroenterology, 114(4):A680, (1998).		
	EJ	Singh, P., et al., "Hormones in colon cancer: past and prospective studies," Cancer Journal, 3:28-33, (1990).		
	EK	Singh, P., et al., "Incomplete processing of progastrin expressed by human colon cancer cells: roles of noncarboxyamidated gastrins," The American Physiological Society, G459-G468, (1994).		
	EL	Singh, P., et al., "Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors," Journal of Biological Chemistry, 270:8429-8435, (1995).		
	EM	Singh, P., et al., "Role of gastrin and gastrin receptors on the growth of a transplantable mouse colon carcinoma (MC-26) in BALB/c Mice," Cancer Research, 46, 1612-1616, (1986).		
Examiner Signature			Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118- 059US2/2838BUS		Application No. 10/829,137	
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Gevas et al.			
				Filing Date April 21, 2004		Group Art Unit 1631	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	EN	Smith, J., et al. "Gastrin regulates the growth of human pancreatic cancer in a tonic and autocrine fashion," American Journal of Physiology, 270(5):R1078-R1084, (1996).					
	EO	Smith, J., et al. "Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines," American Journal of Physiology, 266:R277-283, (1994).					
	EP	Smith, J., et al. "Identification of gastrin as a growth peptide in human pancreatic cancer", American Journal of Physiology, 268:R135-R141, (1995).					
	EQ	Smith, J., et al. "Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease," Gastroenterology, 96:683-689, (1989).					
	ER	Sobhani, I., et al., "Immunohistochemical characterization of gastrinomas with antibodies specific to different fragments of progastrin," Gastroentérologie clinique et biologique., 13:865-872, (1989).					
	ES	Soll, A., et al., "Gastrin-receptors on isolated canine parietal cells," Journal of Clinical Investigation, 73:1434-1447, (1984).					
	ET	Song, I., et al., "The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs," Proceedings of the National Academy of Sciences of the United States of America, 90(19):9085-9089, (1993).					
	EU	Stepan, V., et al., "Glycine-extended gastrin exerts growth-promoting effects on colon cancer cell lines," Molecular Medicine, 5(3):147-159, (1999).					
	EV	Takinami et al., "YF476 is a new patent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo," Alimentary Pharmacology & Therapeutics, 11(1):113-120, (1997).					
	EW	Tang, C., et al., "Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumor-free pancreas," British Journal of Cancer, 75(10):1467-1473 (1997).					
	EX	Taniguchi, T., et al., "Cholecystokinin-B/gastrin receptor signaling pathway involve tyrosine phosphorylatins of p125FAK and p42MAP," Oncogene, 9:861-867, (1994).					
	EY	Tarasova, N., et al., "Endocytosis of gastrin in cancer cells expressing gastrin/CCK-B receptor," Cell and Tissue Research, 287:325-333, (1997).					
	EZ	Todisco, A., et al., "Gastrin and glycine-extended progastrin processing intermediates induce different programs of early gene activation," Journal of Biological Chemistry, 279:28337-28341, (1995).					
	FA	Trakal, E., et al., "[Diagnosis and etiology of Barrett's esophagus: Presence of gastrin secreting cells]" Acta Gastroenterologica Latinoamericana, 15(2):67-80, (1985) [in Spanish, English abstract on first page of article]					
	FB	Vaillant, C., et al., "Cellular origins of different forms of gastrin: The specific immunocytochemical localization of related peptides," Journal of Histochemistry and Cytochemistry, 27:932-935, (1979).					
	FC	Van Vlierberghe, H., et al., "Fundic gland polyps: Three other case reports suggesting a possible associate with acid suppressing therapy," Acta Gastro-Enterologica Belgica, 60(3):240-242,					
	FD	Van-Solinge, W., et al., "Expression but incomplete maturation of progastrin in colorectal carcinomas," Gastroenterology, 104:1099-1107, (1993).					
	FE	Wank, S., "Cholecystokinin receptors (editorial)," American Journal of Physiology, 269:G628-G646, (1995).					
	FF	Wank, S., et al., "Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression," Proceedings of the National Academy of Sciences of the United States of America, 89:8691-8695, (1992).					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118- 059US2/2838BUS	Application No. 10/829,137
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))			Applicant Gevas et al.	
			Filing Date April 21, 2004	Group Art Unit 1631
<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>				
Examiner Initial	Desig. ID	Document		
	FG	Wank, S., et al., "Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human," <i>Annals of the New York Academy of Sciences</i> , 713:49-66, (1994).		
	FH	Watson et al., "Expression of gastrin-CCKB receptor isoforms in gastrointestinal tumor cells," <i>International Journal of Cancer</i> , 77(4):572-577, (1998).		
	FI	Watson, S., et al., "A hepatic invasive human colorectal xenograft model," <i>European Journal of Cancer</i> , 29(12):1740-1745, (1993).		
	FJ	Watson, S.A. and R.J. Steele, "Gastrin antagonists in the treatment of gastric cancer," <i>Anticancer Drugs</i> , 4(6):599-604, (1993).		
	FK	Watson, S.A. and R.J. Steele, "The effect of the E2 prostaglandin enprostil, and the somatostatin analogue sms201995, on the growth of a human gastric cell line, MKN45G," <i>International Journal of Cancer</i> , 45:90-94, (1990).		
	FL	Watson, S.A., et al., "Detection of gastrin receptors on gastrointestinal tumors using the anti-gastrin receptor monoclonal antibody, 2CL," <i>Gut</i> 4: F271, (1993).		
	FM	Watson, S.A., et al., "Antibodies targeting the amino terminal portion of the human CCKB/gastrin receptor inhibit the liver invasion of a human colonic tumor," <i>Gastroenterology</i> , 114(4 Part 2): A701, (Abstract # G2899) (April 15, 1998).		
	FN	Watson, S.A., et al., "Effect of gastrin neutralization on the progression of the adenoma:carcinoma sequence in the Min mouse model of familial adenomatous polyposis," <i>Gastroenterology</i> , 114(Supplement 1):A701, (Abstract #G2900) (April 15, 1998).		
	FO	Weinberg, D., et al., "Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma," <i>Journal of Clinical Investigation</i> , 100(3):597-603, (1997).		
	FP	Wetscher, G., et al., In <i>Gastroesophageal Reflux Disease</i> , R.A. Heinder, ed. R.G. Landes Co., Ch.2, pp7-29, (1993).		
	FQ	Wong, K., et al., "Postprandial hypergastrinaemia in patients with colorectal cancer," <i>Gut</i> , 32:1352-1354, (1991).		
	FR	Yuki, H., et al., "YM022, a patent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heiden hair pouch dogs," <i>Digestive Diseases and Sciences</i> , 42(4):707-714, (1997).		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	